- Home
- AIT vs MRNA Comparison
AIT vs MRNA Comparison
Compare AIT & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIT
- MRNA
- Stock Information
- Founded
- AIT 1923
- MRNA 2010
- Country
- AIT United States
- MRNA United States
- Employees
- AIT N/A
- MRNA N/A
- Industry
- AIT Industrial Machinery/Components
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIT Industrials
- MRNA Health Care
- Exchange
- AIT Nasdaq
- MRNA Nasdaq
- Market Cap
- AIT 9.2B
- MRNA 10.6B
- IPO Year
- AIT N/A
- MRNA 2018
- Fundamental
- Price
- AIT $220.19
- MRNA $24.83
- Analyst Decision
- AIT Strong Buy
- MRNA Hold
- Analyst Count
- AIT 8
- MRNA 20
- Target Price
- AIT $283.75
- MRNA $51.94
- AVG Volume (30 Days)
- AIT 462.5K
- MRNA 8.6M
- Earning Date
- AIT 05-01-2025
- MRNA 05-01-2025
- Dividend Yield
- AIT 0.82%
- MRNA N/A
- EPS Growth
- AIT 4.74
- MRNA N/A
- EPS
- AIT 9.98
- MRNA N/A
- Revenue
- AIT $4,499,369,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- AIT $3.05
- MRNA N/A
- Revenue Next Year
- AIT $7.00
- MRNA $22.14
- P/E Ratio
- AIT $22.41
- MRNA N/A
- Revenue Growth
- AIT 0.50
- MRNA N/A
- 52 Week Low
- AIT $181.35
- MRNA $23.15
- 52 Week High
- AIT $282.98
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- AIT 46.88
- MRNA 42.25
- Support Level
- AIT $213.78
- MRNA $23.70
- Resistance Level
- AIT $224.00
- MRNA $28.52
- Average True Range (ATR)
- AIT 7.45
- MRNA 1.34
- MACD
- AIT -1.01
- MRNA -0.03
- Stochastic Oscillator
- AIT 30.12
- MRNA 29.80
About AIT Applied Industrial Technologies Inc.
Applied Industrial Technologies Inc is a distributor of industrial products to the maintenance, repair, and operations market and the original equipment manufacturing industry. Further, the company provides engineering and design services for industrial and fluid power applications. The products include bearings, power transmission components, fluid power components and systems, industrial rubber products, linear motion components, safety products, oilfield supplies, and other industrial and maintenance supplies. The company's reportable segments are; Service Center Based Distribution which derives key revenue, and Engineered Solutions. Geographically, the company derives its key revenue from the United States and the rest from Canada and other countries.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.